Connect with us

Health

What if Canada gets an outbreak of the new coronavirus? A look at… – Todayville.com

Published

 on



OTTAWA — Rudy Husny scrambled up and down the stairs of the House of Commons Wednesday, thrusting his nomination papers for the Conservative leadership in front of one party member after another as he hustled to collect enough names to enter the contest.

With Thursday the deadline to register, Husny is among those racing to submit the first $25,000 needed to run, along with the first set of signatures — from 1,000 people, spread across 30 ridings in seven provinces and territories.

But with the party verifying each name, and rejecting dozens from most campaigns as unqualified to support the bids, Husny is aiming to hand the party more than required to ensure he gets in.

“I’m making sure I’ve got it all,” he said as he scurried off to buttonhole someone else on Parliament Hill.

So far, the race has six official contenders, with two added this week: new Ontario MP Derek Sloan and Ontario party activist Jim Karahalios. They join Ontario MP Marilyn Gladu and Toronto lawyer Leslyn Lewis as “approved candidates,” meaning they’ve met the first set of requirements to run. 

Ahead of them are two others: former cabinet ministers Peter MacKay and Erin O’Toole. They’ve moved from the first stage to the second by laying down a further $25,000 of the registration fee, a full $100,000 refundable compliance deposit, and another 1,000 signatures, making them “authorized contestants.”

What that gives them is the party’s coveted membership list, so they can start contacting existing members to solicit support and money.

By March 25, all candidates must submit a total of 3,000 signatures, the full non-refundable $200,000 entry fee and the $100,000 refundable compliance deposit.

Those who hit those benchmarks must also participate in two official debates. The party announced Wednesday there will be an English-language debate in Toronto on April 17 and a French one on April 23 in Montreal.

The date takes into account the March 25 deadline, said Dan Nowlan, one of the two chairs of the party’s leadership organizing committee.

“The decision to hold the debates at this point of the race means candidates appearing on the stage are actually those that will appear on the ballot,” he said.

But Thursday’s cut-off is still significant, said Brad Trost, a previous leadership candidate.  

“It is meaningful to ordinary members, people who write cheques and who are deciding who to support,” Trost said.

“This will mean someone is an official candidate, and that sends a signal.”

Getting the first batch of signatures, the money and the application in by Thursday is no guarantee a candidate will be approved. In addition to vetting the signatures, the party’s organizing committee reserves the right to interview applicants and reject their candidacies. 

Richard Decarie, a Quebec candidate strongly opposed to abortion and same-sex marriage, is still waiting on his interview though has submitted the initial materials, Trost said.

There have been calls for the party to bar Decarie from running.

Current leader Andrew Scheer’s opposition to abortion and unclear stance on same-sex marriage were perceived as liabilities in the last federal election, though he never really discussed in detail his beliefs and said he wouldn’t support any legislation restricting either.

Decarie, on the other hand, has said he would defund abortion and restore the “traditional” definition of marriage as being between a man and a woman. His comments, including his position that being LGBTQ is a choice, have been condemned by prominent members of the party.

Sloan holds similar views; he said last month the science isn’t clear on whether being gay is a choice. The party approved his application this week. 

Quebec movie-theatre mogul Vincenzo Guzzo, who also appears on the reality TV show “Dragons’ Den,” said he’s got the application materials in hand but is thinking over whether he’s going to hand them in.

He said he’s not sure the race is set up to accommodate relative political outsiders, nor whether he can adjust his business interests accordingly, considering the tight timelines.

“Whether I decide to run or not, one thing is for sure,” Guzzo said.

“I’m not going away.” 

Party members are to elect a new leader on June 27.

This report by The Canadian Press was first published Feb. 26, 2020.

Stephanie Levitz, The Canadian Press

Let’s block ads! (Why?)



Source link

Continue Reading

Health

UBC researchers say they've found 'weak spot' in all COVID-19 variants that could lead to better treatment – CBC.ca

Published

 on


Researchers at the University of British Columbia (UBC) have discovered what they describe as a “weak spot” in all of the major variants of the virus that causes COVID-19 — a revelation they believe could open the door for treatments to fight current and future mutations.

In a peer-reviewed study published Thursday, the research team said they found a largely consistent soft spot — like a dent in the virus’s spike protein armour — that has survived the coronavirus’s mutations to date. Scientists determined a certain antibody fragment was able to “effectively neutralize” all the variants, to some degree, because it exploited the vulnerability.

“What’s exciting is what it tells us we can do now. Once you know the [weak] spot, it’s a bit like the gold rush analogy. We know where to go,” said Sriram Subramaniam, the study’s senior author and a professor with UBC’s faculty of medicine.

“We can now use this information … to design better antibodies that can then take advantage of that [weak] site.”

Looking for the ‘master key’

Antibodies are naturally produced by the body to fight infection, but can also be created in a laboratory to administer as treatment. Several antibody treatments already exist to fight COVID-19, but their effectiveness fades against highly mutated variants like the recently dominant Omicron. 

“Antibodies attach to a virus in a very specific manner, like a key going into a lock. But when the virus mutates, the key no longer fits,” Subramaniam wrote in a statement.

“We’ve been looking for master keys — antibodies that continue to neutralize the virus even after extensive mutations.” 

A nurse provides information to parents and children during the first week of COVID-19 immunization for children over six months at a Vancouver Coastal Health clinic in Vancouver on Aug. 4. (Ben Nelms/CBC)

Subramaniam said the antibody fragment identified in the paper would be that “master key.”

Matthew Miller, director of the DeGroote Institute for Infectious Disease Research at McMaster University in Hamilton, Ont., described the findings as “a really important development” in the fight against COVID-19.

“It’s been able to show that this antibody works against all of them and that’s really unique…. It certainly raises the hope that this [weak] area they’re targeting would be an area the virus would have a lot of trouble changing — even going forward, because if it were easy to change, it’s very likely [the virus] would have tried to change it already,” said Miller, who was not involved in the study.

“Now … viruses can always trick us,” he noted in an interview Thursday. “They’re smart. There’s always ways out. But what we want to do is make it as hard as possible to do that.”

High-tech imaging used to study virus

As part of the study, published in Nature Communications, the research team used a process called cryo-electron microscopy (cryo-EM) to examine the weak spot on the virus’s spike protein, called an epitope.

Cryo-EM technology involves freezing samples of the virus and taking hundreds of thousands of photos — similar to X-rays — used to recreate a 3D model of the molecule from an atomic level.

“Imagine you were the size of an atom and you could watch exactly what was going on,” Subramaniam explained.

Through the process, the team saw how antibodies interacted with virus. The antibody fragment, called VH Ab6, was able to latch on to the weak spot and neutralize the virus.

Subramaniam said drug companies could exploit the weakness to create a potentially “variant-resistant” treatment.

  • Do you have a coronavirus question or news tip for CBC News? Email us at ask@cbc.ca

The researcher noted that developments resulting from the team’s discovery won’t be part of COVID-19 treatment in clinics for some time, but he described it as one more step in understanding the coronavirus itself and the illness it causes.

“We never know if this antibody will suddenly not be effective against the next variant or not…. But we’re just saying that it stood up really well to being able to neutralize the variants we’ve seen to date,” Subramaniam said.

The UBC team collaborated with colleagues at the University of Pittsburgh, who have been screening large antibody libraries and testing their effectiveness against COVID-19.

Adblock test (Why?)



Source link

Continue Reading

Health

U.S. offers extra monkeypox vaccine doses for gay pride events – CTV News

Published

 on


NEW YORK –

The U.S. is setting aside an extra 50,000 doses of monkeypox vaccine for places with upcoming gay pride events, health officials said Thursday.

The number of doses sent to each place will be based on factors like the size of the event, how many health workers will be available to give shots, and how many of the attendees are considered at highest risk for catching the virus.

“More shots in arms is how we get the outbreak under control,” Bob Fenton, the White House monkey pox response coordinator, told reporters Thursday. He said the effort is an attempt to “meet people where they are.”

At least a dozen U.S. pride events are scheduled over the next two months, including large gatherings in Atlanta and New Orleans in early September. U.S. officials said they will send up to 2,000 additional doses to North Carolina, where the Charlotte Pride Festival & Parade will be held this weekend.

Southern Decadence, one of the nation’s largest LGBTQ events, is expected to attract 200,000 or more people to New Orleans over Labour Day weekend. The Bourbon Street Extravaganza, a free concert held amid the event, has been cancelled over monkey pox concerns, organizers said this week.

Frank Perez, a former grand marshal of the parade that’s the centrepiece of Southern Decadence, said a number of New Orleans gay bars have already had vaccine events. He said so far officials have done an adequate job with the vaccine campaign although “more is better.”

Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, cautioned: “While we are offering the vaccine at these events to those at high risk, this is a two-dose vaccine series, and receiving the vaccine at the event will not provide protection at the event itself.”

Health officials also are urging other steps to prevent the spread of the virus, including temporarily limiting sexual partners.

Monkeypox is endemic in parts of Africa, where people have been infected through bites from rodents or small animals, but it wasn’t considered a disease that spreads easily among people until May, when infections emerged in Europe and the U.S.

There have been more than 39,000 cases reported in countries that have not historically seen monkey pox. The vast majority have occurred in men who have sex with men, but health officials stress that anyone can get monkey pox.

The U.S. has the most infections of any country – more than 13,500. About 98% of U.S. cases are men and about 93% were men who reported recent sexual contact with other men.

Officials say the virus has been spreading mainly through skin-on-skin contact, but they warn it might also transmit in other ways, including through touching linens used by someone with monkey pox.

People with monkey pox may experience fever, body aches, chills and fatigue. Many in the outbreak have developed extremely painful zit-like bumps. No one in the U.S. has died, but deaths have been reported in other countries.

The U.S. has a limited supply of what is considered the main weapon against the virus – a vaccine called Jynneos. The doses are currently being given to people soon after they think they were exposed. Scientists are still trying to establish how well the shots are working.

The government last week moved to stretch the supply by giving people one-fifth the usual dose, injected just under the skin, instead of a full vial injected into deeper tissue.

Many health workers may have little experience giving shots using the just-under-the-skin method, which requires different needles and syringes. Some health departments have started doing that, but some local officials have said they may need a week or more to make the change.

Officials this week announced the release of 442,000 of the smaller doses for order by state, local and territorial health departments. On Thursday, they said more is coming next week – 1.8 million doses, or 360,000 vials.

Officials also announced a new agreement with a Michigan manufacturer to help speed production of 5.5 million vaccine vials recently ordered by the U.S. government.

Under the deal, Grand River Aseptic Manufacturing will help package raw vaccine ingredients currently stored at an overseas facility owned by Bavarian Nordic, which makes the Jynneos vaccine. Officials said the extra capacity should help speed up U.S. vaccine orders, most of which weren’t expected to be delivered until next year. The Biden administration has faced weeks of criticism for not ordering more vaccine sooner.

Also on Thursday, health officials said next week they will boost the supply of TPOXX, a drug for treating monkey pox infections, by 50,000 treatment courses.

——

AP reporters Rebecca Santana in New Orleans and Matthew Perrone in Washington contributed to this report.

Adblock test (Why?)



Source link

Continue Reading

Health

‘Weak spot’ in virus responsible for COVID-19 could mean new treatments: researchers

Published

 on

VANCOUVER — Researchers at the University of British Columbia have discovered what they are calling a “weak spot” in the virus that causes COVID-19.

A study published in the peer-reviewed scientific journal Nature Communications says the “key vulnerability” is found in all major variants of the SARS-CoV-2 virus.

Researchers say exploiting that weakness could pave the way for new treatments that would be effective against all strains of the illness that has killed almost 6.5-million people across the globe since it was identified more than two years ago.

The study’s senior author, Dr. Sriram Subramaniam, a professor in UBC’s faculty of medicine, says the team studied the virus at an atomic level, found the weak spot and identified an antibody fragment that can attach to it and all other variants, including the surging Omicron subvariants.

Antibodies counteract viruses by attaching like a key in a lock and are no longer effective when the virus mutates quickly, but Subramaniam says the weak spot is constant in all seven major variants of the SARS-CoV-2 virus, allowing one antibody to act as a “master key” capable of overcoming extensive mutations.

Subramaniam says the weak spot and master key identified in the study “unlock a whole new realm of treatment possibilities” that have the potential to be effective against current or future variants of the virus that causes COVID-19.

This report by The Canadian Press was first published Aug. 18, 2022.

 

The Canadian Press

Continue Reading

Trending